Cingulate Ownership
| CING Stock | USD 3.70 0.11 3.06% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Cingulate |
Cingulate Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 1.08. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cingulate recorded a loss per share of 43.22. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 9th of August 2024. Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficithyperactivity disorder. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Cingulate operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people. For more info on Cingulate please contact Shane PharmD at 913 942 2300 or go to https://www.cingulate.com.Cingulate Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cingulate is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cingulate backward and forwards among themselves. Cingulate's institutional investor refers to the entity that pools money to purchase Cingulate's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goalvest Advisory Llc | 2024-09-30 | 0.0 | Fmr Inc | 2024-12-31 | 0.0 | Headlands Technologies Llc | 2024-12-31 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Virtu Financial Llc | 2024-09-30 | 0.0 | Commonwealth Equity Services Inc | 2024-12-31 | 43 K | Geode Capital Management, Llc | 2024-12-31 | 27.3 K | Ubs Group Ag | 2024-12-31 | 12.2 K | Alphamark Advisors, Llc | 2024-12-31 | 5 K | Bank Of America Corp | 2024-12-31 | 2 K |
Cingulate Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cingulate insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cingulate's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cingulate insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cingulate Outstanding Bonds
Cingulate issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cingulate uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cingulate bonds can be classified according to their maturity, which is the date when Cingulate has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US172441BF30 Corp BondUS172441BF30 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Cingulate Corporate Filings
8K | 4th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 20th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 15th of October 2024 Other Reports | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Cingulate is a strong investment it is important to analyze Cingulate's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cingulate's future performance. For an informed investment choice regarding Cingulate Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cingulate. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cingulate. If investors know Cingulate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cingulate listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cingulate is measured differently than its book value, which is the value of Cingulate that is recorded on the company's balance sheet. Investors also form their own opinion of Cingulate's value that differs from its market value or its book value, called intrinsic value, which is Cingulate's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cingulate's market value can be influenced by many factors that don't directly affect Cingulate's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cingulate's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cingulate is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cingulate's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.